TRD1 Project Summary/Abstract This Technology Research & Development (TRD) project in the Hyperpolarized MRI Technology Resource Center (HMTRC) is responsible for developing, maintaining and improving the “beyond state-of-the-art” polarizer and MRI hardware technologies required for all hyperpolarized (HP) 13C MRI studies performed & supported by this P41 Center’s TRDs, CPs and SPs. Since its inception in 2011, this TRD has been highly successful in developing and disseminating novel technologies for preclinical HP MRI worldwide, and driving first-ever HP 13C studies in humans. As stated in the recent External Advisory Committee’s 2021 report: “Since the last competitive renewal, the number of sites that have begun acquiring data from human subjects has risen from one – UCSF – to twelve, all of which have been supported by the HMTRC. Of the 36 trials that are registered on ClinicalTrials.gov, the majority (21) are now being carried out at other institutions that have benefitted from the outstanding leadership of the HMTRC… The HMTRC has led the nation (and the world) in the development and translation of HP MRI through a unique combination of skills, expertise, instrumentation, environment, clinical engagement, and industry engagement, which simply does not exist elsewhere”. In this renewal project, new dissolution DNP technology will be developed by TRD1 to achieve higher polarizations for HP probes (TRD2), driven by the needs of all CPs with iterative push-pull optimization & specialized training. TRD1 technology resources will be disseminated and used by SPs and the international HP 13C scientific community with feedback on performance, quality of training, and ease of dissemination. TRD1 will develop improved polarization, dissolution and sample delivery technologies required for all CPs, SPs and TRDs. New DNP and MR hardware for preclinical studies will be driven by the needs of CPs together with TRD2. Clinical innovation will be driven by CP1,3-6,8-10,13. The HP pharmacy team will create robust, reduced-cost, sterile HP 13C-probe manufacturing methods that meet FDA guidelines. TRD1 will develop novel 13C RF exciters and detectors, working closely with TRD3 to create and test new methods for data reconstruction, visualization and analysis. These methods will be developed in a push-pull fashion, driven by the CPs for metabolic imaging of liver disease (CP2,6), cardiac disease (CP2), cancer (CP1,3,4,8,9,13), brain disorders (CP5,10) and HP perfusion imaging (CP7). A major focus of this TRD1 project will also be the specialized training of new intra- & extramural investigators both through hands-on training at this P41 center and via webconferences, on-line website documentation, training modules and videos.